Early results show that the combination of VXM01 plus avelumab demonstrated tolerable safety in recurrent glioblastoma.

Treatment with VXM01, an investigational vaccine, plus Bavencio demonstrated both safety and tolerability in patients with ...

Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further ...

The reported safety and tolerability data, together with early indications for the potential relevance of a VXM01dependent, VEGFR-2 specific ... available bacterial vaccine strain, which is ...

“Mikael has a long and successful track record overseeing the development of blockbuster therapies and vaccines from discovery ... growth factor receptor (VEGFR) inhibitor Inlyta (axitinib ...

The reported safety and tolerability data, together with early indications for the potential relevance of a VXM01dependent, VEGFR-2 specific immune response ... orally available bacterial vaccine ...

Building upon its already impressive obesity drug portfolio, Novo Nordisk A/S has licensed a triple agonist of the receptors for GLP-1, GIP and glucagon from United Biotechnology Co. Ltd. China-based ...